Allogene Therapeutics (ALLO) Non-Current Assets (2018 - 2026)

Allogene Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $122.7 million in Q1 2026.

• Quarterly Non-Current Assets fell 43.32% year-over-year to $122.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $647.8 million (down 30.8% YoY) and the FY2025 annual result came in at $158.2 million, down 35.53% from the prior year.
• Non-Current Assets declined to $122.7 million in Q1 2026 per ALLO's latest filing, from $158.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $508.3 million in Q1 2022 and troughed at $122.7 million in Q1 2026.
• A 5-year average of $253.4 million and a median of $240.0 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets sank 49.48% in 2022, then soared 33.53% in 2024.
• Over 5 years, Non-Current Assets stood at $292.8 million in 2022, then sank by 37.24% to $183.7 million in 2023, then surged by 33.53% to $245.3 million in 2024, then slumped by 35.53% to $158.2 million in 2025, then retreated by 22.44% to $122.7 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $122.7 million, $158.2 million, and $179.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.